BRPI0407374A - Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv - Google Patents

Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv

Info

Publication number
BRPI0407374A
BRPI0407374A BR0407374-6A BRPI0407374A BRPI0407374A BR PI0407374 A BRPI0407374 A BR PI0407374A BR PI0407374 A BRPI0407374 A BR PI0407374A BR PI0407374 A BRPI0407374 A BR PI0407374A
Authority
BR
Brazil
Prior art keywords
group
alkyl
formula
infections
phosphate
Prior art date
Application number
BR0407374-6A
Other languages
English (en)
Inventor
Hiromichi Tanaka
Masanori Baba
Yung-Chi Cheng
Original Assignee
Univ Yale
Hiromichi Tanaka
Masanori Baba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Hiromichi Tanaka, Masanori Baba filed Critical Univ Yale
Publication of BRPI0407374A publication Critical patent/BRPI0407374A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ANáLOGOS DE NUCLEOSìDEO ANTIVIRAL E MéTODOS PARA TRATAR INFECçõES VIRAIS, ESPECIALMENTE INFECçõES DE HIV". A presente invenção refere-se a novos compostos de acordo com as Fórmulas gerais (I, II, III, IV ou V); em que B é base de nucleosídeo de acordo com a Fórmula de estrutura (VI); R é H, F, CI, Br, I, C~ 1~-C~ 4~ alquila (preferivelmente CH~ 3~), -C=N, -C=-C-R~ A~, Formula (VII); X é H, C~ 1~-C~ 4~ alquila (preferivelmente, CH~ 3~), F, CI, Br ou I; Z é O ou CH2, com a condição de que Z é CH~ 2 e não O quando o composto é de acordo com a fórmula geral II, R¬ 3¬ é -C=-C-H e R¬ 2¬ é H ou um grupo fosfato, difosfato, trifosfato ou fosfotriéster; R¬ 1¬ é H, um grupo acila, um grupo C~ 1~-C~ 20~ alquila ou de éter; R¬ 2¬ é H, um grupo acila, um grupo C~ 1~-C~ 20~ alquila ou de éter. Um grupo fosfato, difosfato, trifosfato, fosfodiéster ou um grupo de Fórmula (VIII) ou Fórmula (IX); Nu é um radical de um composto antiviral biologicamente ativo tal que um grupo amina ou grupo hidroxila do referido composto antiviral biologicamente ativo forma um grupo fosfato, fosforamidato, carbonato ou uretano com a porção adjacente; R8 é H, ou um grupo C~ 1~-C~ 20~ alquila ou éter, preferivelmente um grupo C~ 1~-C~ 12~ alquila; k é 0-12, preferivelmente, 0-2; R3 é selecionado de um grupo C~ 1~-C~ 4~ alquila (preferivelmente, CH3), -(CH2)n-C=-C-Ra, Fórmula (X) ou Fórmula (XI); R3a e R3b sejam independentemente selecionados de H, F, CI, Br ou I; R4 e R5 são independentemente selecionados de H, F, CI, Br, I, OH, C~ 1~-C~ 4~ alquila (preferivelmente, CH3), -(CH2)n-C=-C-Ra, Fórmula (XII) ou Fórmula (XIII) com a condição de que R4 e R5 não são ambos H; Ra é H, F, CI, Br, I, OU -C~ 1~-C~ 4~ alquila, preferivelmente H ou CH3; Y é H, F, CI, Br, I ou C~ 1~-C~ 4~ alquila, preferivelmente H ou CH3; e n é 0, 1, 2, 3, 4 ou 5, preferivelmente 0, 1 ou 2; e anómeros dos mesmos, sais, solvatos ou polimorfos farmaceuticamente aceitáveis dos mesmos.
BR0407374-6A 2003-02-19 2004-02-18 Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv BRPI0407374A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44855403P 2003-02-19 2003-02-19
PCT/US2004/004713 WO2005011709A1 (en) 2003-02-19 2004-02-18 Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections

Publications (1)

Publication Number Publication Date
BRPI0407374A true BRPI0407374A (pt) 2006-01-10

Family

ID=34115263

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407374-6A BRPI0407374A (pt) 2003-02-19 2004-02-18 Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv

Country Status (13)

Country Link
US (3) US7589078B2 (pt)
EP (2) EP1653976A4 (pt)
JP (1) JP4980059B2 (pt)
KR (2) KR101228503B1 (pt)
CN (2) CN102174038A (pt)
AU (1) AU2004260630B2 (pt)
BR (1) BRPI0407374A (pt)
CA (1) CA2514466C (pt)
EA (1) EA012844B1 (pt)
MX (1) MXPA05008736A (pt)
PL (2) PL219609B1 (pt)
WO (1) WO2005011709A1 (pt)
ZA (1) ZA200506630B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
CN102174038A (zh) 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
BRPI0417988A (pt) * 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
CA2584670A1 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
WO2007065032A2 (en) * 2005-12-02 2007-06-07 The Regents Of The University Of California Compounds and methods for inhibiting viral entry
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
US20080078560A1 (en) * 2006-10-02 2008-04-03 Kevin Hall Motor seal
ES2438275T3 (es) * 2007-07-06 2014-01-16 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
EP2228373B1 (en) * 2007-12-27 2017-02-08 Oncolys BioPharma, Inc. METHOD FOR PRODUCING 4'-ETHYNYL d4T
WO2009119785A1 (ja) * 2008-03-28 2009-10-01 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
US8445669B2 (en) 2008-04-10 2013-05-21 Hamari Chemicals, Ltd. Production process of ethynylthymidine compounds from 5-methyluridine as a starting material
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
US8759318B2 (en) * 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
CN104856991A (zh) 2009-02-27 2015-08-26 西佳技术公司 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2537839B1 (en) 2010-02-15 2016-12-14 Nissan Chemical Industries, Ltd. B-dihydrofuran deriving compound, method for producing b-dihydrofuran deriving compound or b-tetrahydrofuran deriving compound, b -glycoside compound, method for producing b-glycoside compound, and method for producing 4'-ethynyl d4t and analogue compounds thereof
JP5765536B2 (ja) 2010-02-15 2015-08-19 日産化学工業株式会社 β−グリコシド化合物の製造方法
WO2011126082A1 (ja) 2010-04-07 2011-10-13 日産化学工業株式会社 アシロキシピラノン化合物の製造方法、アルキン化合物の製造方法及びジヒドロフラン化合物の製造方法
WO2012048271A1 (en) * 2010-10-08 2012-04-12 The Board Of Trustees Of The University Of Illinois Phosphoramidate derivatization of inorganic polyphosphates and methods
WO2012166645A1 (en) * 2011-06-01 2012-12-06 Syndax Pharmaceuticals, Inc. Prodrugs of azacitidine 5' -diphosphate
WO2013066991A1 (en) * 2011-10-31 2013-05-10 Inhibitex, Inc. Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease
SG10201913554YA (en) * 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2852583A1 (en) * 2012-05-23 2015-04-01 Bristol-Myers Squibb Company Sulfilimine and sulphoxide methods for producing festinavir
US20160060252A1 (en) 2013-04-16 2016-03-03 Bristol-Myers Squibb Company 5-methyluridine method for producing festinavir
GB201306947D0 (en) * 2013-04-17 2013-05-29 Univ Leuven Kath Novel antiviral compounds
WO2014201122A1 (en) 2013-06-13 2014-12-18 Bristol-Myers Squibb Company Tert-butyl-sulphoxide method for producing festinavir
US10683321B2 (en) * 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
AU2015320511B2 (en) * 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
WO2016069489A1 (en) * 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
EP3377177A2 (en) 2015-11-20 2018-09-26 VIIV Healthcare UK(No.4) Limited Hiv maturation inhibitor formulations
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
AU2018335411B2 (en) * 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
KR101893988B1 (ko) * 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물
TW202019941A (zh) 2018-07-27 2020-06-01 日商富士軟片股份有限公司 環丁基嘌呤衍生物或其鹽
WO2020022486A1 (ja) * 2018-07-27 2020-01-30 富士フイルム株式会社 シクロペンテニルプリン誘導体またはその塩
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN109761842B (zh) * 2019-02-01 2021-11-30 浙江工业大学 α-F-β-NHAc-羰基化合物的合成方法
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4423100A4 (en) * 2021-10-29 2025-04-23 University of Georgia Research Foundation, Inc. PRODRUGS OF L-BHDU AND METHODS FOR THE TREATMENT OF VIRUS INFECTIONS
KR20230130898A (ko) 2022-03-04 2023-09-12 동아대학교 산학협력단 N4-이소부티릴옥시시티딘 모방체 합성과 이의 항바이러스 용도를 포함하는 바이러스 감염 치료용 조성물
WO2024015916A2 (en) * 2022-07-13 2024-01-18 Thomas Jefferson University 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5179084A (en) 1989-04-10 1993-01-12 Nippon Kayaku Kabushiki Kaisha Antiviral phosphoric acid esters of oxetanocins
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
US5739396A (en) * 1991-12-09 1998-04-14 Stanford University Asymmetric ligands useful for transition metal catalyzed bond forming reactions
JPH05230058A (ja) * 1992-02-24 1993-09-07 Yamasa Shoyu Co Ltd ４’−炭素置換ピリミジンヌクレオシド及びその製造法
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
JPH0680688A (ja) * 1992-09-03 1994-03-22 Asahi Breweries Ltd ４’−メチルヌクレオシド誘導体
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
NZ297100A (en) * 1994-12-13 1997-10-24 Akira Matsuda 3'-substituted nucleoside derivatives; medicaments
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
CA2226363C (en) * 1996-05-16 2001-03-13 Taiho Pharmaceutical Co., Ltd. D-pentofuranose derivatives and process for preparing the same
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU6358898A (en) 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
JP3792005B2 (ja) 1997-04-24 2006-06-28 彰 松田 ２−デオキシ−３−エチニル−β−Ｄ−リボフラノシル誘導体
CA2293508A1 (en) 1997-06-04 1998-12-10 Louis Nickolaus Jungheim Anti-viral compounds
JP4211901B2 (ja) 1998-06-08 2009-01-21 ヤマサ醤油株式会社 ４’−メチルヌクレオシド化合物
KR20010079907A (ko) 1998-09-25 2001-08-22 비로파마 인코포레이티드 바이러스 감염 및 관련 질병의 치료 및 예방 방법
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
US6240690B1 (en) 2000-02-02 2001-06-05 Roof & Metal Systems, Inc. Vented metal roof
RU2182013C1 (ru) 2001-03-05 2002-05-10 Казанцева Наталья Вениаминовна Способ лечения нейродегенеративных заболеваний мозга
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
EP1572705A2 (en) * 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
CN102174038A (zh) * 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷

Also Published As

Publication number Publication date
WO2005011709A1 (en) 2005-02-10
JP2006528972A (ja) 2006-12-28
US7589078B2 (en) 2009-09-15
ZA200506630B (en) 2006-06-28
EP1653976A4 (en) 2009-07-29
MXPA05008736A (es) 2005-10-05
CN102174038A (zh) 2011-09-07
EA012844B1 (ru) 2009-12-30
US20120252751A1 (en) 2012-10-04
HK1087341A1 (en) 2006-10-13
US8193165B2 (en) 2012-06-05
KR20060026402A (ko) 2006-03-23
EP1653976A1 (en) 2006-05-10
US20040167096A1 (en) 2004-08-26
EP2298783A1 (en) 2011-03-23
PL398295A1 (pl) 2012-05-21
PL219609B1 (pl) 2015-06-30
EA200501325A1 (ru) 2006-02-24
CN1777432B (zh) 2011-06-08
JP4980059B2 (ja) 2012-07-18
KR101228503B1 (ko) 2013-01-31
KR20110079783A (ko) 2011-07-07
AU2004260630A1 (en) 2005-02-10
AU2004260630B2 (en) 2009-12-10
CA2514466C (en) 2015-05-26
US20100048500A1 (en) 2010-02-25
EP2298783B1 (en) 2017-12-06
CN1777432A (zh) 2006-05-24
PL378354A1 (pl) 2006-03-20
CA2514466A1 (en) 2005-02-10
US9126971B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
BRPI0407374A (pt) Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv
EP0820461B1 (en) Aryl-ester phosphoramidate derivatives of 2',3'-didehydronucleosides
RU2764767C2 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
BRPI0112646B8 (pt) pró-fármacos de análogos de nucleotídeo de fosfonato e composições que as compreende
PT1201678E (pt) Novos analogos biciclonucleosidos
RU2011133900A (ru) Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
AR034448A1 (es) Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones
AR086372A1 (es) Nucleosidos de n2’-fluoro-6’-metilencarbociclicos utiles como agentes antivirales y composiciones farmaceuticas que los contienen
MX2009005120A (es) Compuestos quimicos.
AU2017324939A1 (en) 2'-substituted-N6-Substituted Purine Nucleotides for Rna Virus Treatment
IL173586A0 (en) Use of nucleoside analogues and doxorubicin in medicaments for treating leukemia
BR0114253A (pt) Antagonistas de receptor de glutamato metabotrópico
EP0357571A3 (en) Pyrimidine nucleosides and intermediates
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
AU7187981A (en) Aryloxypropanolamines
KR970701198A (ko) 3'-치환 뉴클레오시드 유도체(3'-substituted nucleoside derivative)
AR049385A1 (es) Sulfoniletil fosforodiamidatos
WO2007067364A3 (en) Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
WO2015158317A8 (en) Use of a l,3j5-triazin-2-yl phosphoramidate compound in the synthesis of sofosbuvir
EA200800002A1 (ru) Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
WO2008035228A3 (en) 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
Valiaeva et al. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy) propyl] nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication
WO2004110379A3 (en) A1 adenosine receptor antagonists
PT991650E (pt) Novos compostos de n-benzenosulfonilo-1-prolina processo de preparacao e utilizacao em terapia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]